2019
DOI: 10.1111/petr.13425
|View full text |Cite
|
Sign up to set email alerts
|

Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient

Abstract: Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a potent immunosuppressant that is increasingly used in prevention and treatment of graft‐vs‐host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) patients. However, data regarding its adverse effects in HSCT patients remain limited. We describe an 18‐year‐old HSCT patient with a history of invasive fungal infection, who developed pericardial effusion with cardiac tamponade and interstitial pneumonitis while receiving sirolim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…One report discusses alemtuzumab [9]. Scattered reports, as well as the European Society of Cardiology guidelines, discuss cyclosporine-associated [8,14] and sirolimus-associated pericardial effusions [15]. Firstline treatment for SAA is triple immunosuppression with hATG, cyclosporine, and the thrombomimetic agent eltrombopag (rarely romiplostim) [16].…”
Section: Discussionmentioning
confidence: 99%
“…One report discusses alemtuzumab [9]. Scattered reports, as well as the European Society of Cardiology guidelines, discuss cyclosporine-associated [8,14] and sirolimus-associated pericardial effusions [15]. Firstline treatment for SAA is triple immunosuppression with hATG, cyclosporine, and the thrombomimetic agent eltrombopag (rarely romiplostim) [16].…”
Section: Discussionmentioning
confidence: 99%